FierceBiotech

@FierceBiotech

Tweets by the Fierce Life Sciences editorial team. Subscribe to our daily email newsletter at

Washington, DC
Vrijeme pridruživanja: prosinac 2008.

Tweetovi

Blokirali ste korisnika/cu @FierceBiotech

Jeste li sigurni da želite vidjeti te tweetove? Time nećete deblokirati korisnika/cu @FierceBiotech

  1. prije 18 sati

    Glenmark officially unveiled Ichnos in October. Its headquarters, as well as a development site, are in Paramus, New Jersey, but it maintains R&D sites overseas

    Poništi
  2. prije 19 sati

    Some of that cash will be used to help boost the launch of Palforzia, but it’s immediately eyeing the future, spending a mere $10 million upfront, with $385 million in biobucks wedded to it, to license Xencor’s XmAb7195.

    Poništi
  3. prije 19 sati

    Regeneron has previously applied its antibody discovery capabilities to pathogens including Ebola and Middle East respiratory syndrome coronavirus (MERS-CoV).

    Poništi
  4. prije 20 sati
    Poništi
  5. prije 20 sati

    Lyon, France-based MaaT is one of a clutch of drug developers trying to treat disease by restoring the microbiome.

    Poništi
  6. 4. velj

    Passage ended 2019 with $158.9 million in the bank and now expects its phase 1/2 gangliosidosis trial to kick off in the second half of 2020, with trials for the dementia and Krabbe candidates to follow in the first half of 2021

    Poništi
  7. 4. velj

    Bio Fund III dwarfs its two predecessors, which totaled $650 million together. And that’s not all—a16z has built a team around its biotech and healthcare efforts.

    Poništi
  8. 4. velj

    Vanda publicly framed its lawsuit against the FDA as a stand against “unnecessary animal research.”

    Poništi
  9. 4. velj

    She comes to the company half a year after Humphrey, who had headed up immuno-oncology at AstraZeneca and Eli Lilly, made her exit.

    Poništi
  10. 4. velj

    BioMotiv, an accelerator linked to the $340 million Harrington Project for Discovery & Development, teamed up with Bristol-Myers in September.

    Poništi
  11. 4. velj

    Bio Fund III dwarfs its two predecessors, which totaled $650 million together. And that’s not all—a16z has built a team around its biotech and healthcare efforts.

    Poništi
  12. 3. velj

    Insmed licensed INS1007 from AstraZeneca in October 2016 for $30 million upfront and $120 million in milestones down the line.

    Poništi
  13. 3. velj

    Gilead publicly floated the idea of using remdesivir to treat the coronavirus, dubbed 2019-nCoV, 10 days ago. Since then, the effort to advance the drug in the indication has gathered pace.

    Poništi
  14. 3. velj

    Craig Basson joins the early-stage private biotech after serving at the Swiss Big Pharma for a decade

    Poništi
  15. 3. velj

    CEPI is supporting programs to develop coronavirus vaccines underway at groups including Inovio Pharmaceuticals and Moderna. The agreement with GSK positions CEPI to expand the support it can offer partner organizations

    Poništi
  16. 31. sij

    VX-961 fell at the first hurdle. On Vertex’s fourth-quarter results conference call with investors, Reshma Kewalramani, the company’s chief medical officer, said the phase 1 showed VX-961 lacked the desired pharmacokinetic and tolerability profile.

    Poništi
  17. 31. sij
    Poništi
  18. 31. sij

    The bad news? These percentages drop for both women and people of color as you look up the ranks. Women make up 30% of executive teams and 18% of biotech company board members, while those numbers are 15% and 14% for people of color, respectively.

    Poništi
  19. 30. sij

    At the bottom of page 17 of its financial presentation, released as part of its full-year/Q4 results, are three experimental drugs stuck at the bottom of table with a big red arrow pointing down: Translation, they’ve been cut.

    Poništi
  20. 30. sij

    Ivarsson joins Moderna as it drives its hefty pipeline forward. One would think that with 21 programs, Moderna has its hands full. But it looks like the mRNA biotech is planning to build out its pipeline even more.

    Poništi

Čini se da učitavanje traje već neko vrijeme.

Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.

    Možda bi vam se svidjelo i ovo:

    ·